Indoco Remedies Ltd.

NSE: INDOCO | BSE: 532612 | ISIN: INE873D01024 | Industry: Pharmaceuticals
| Momentum Trap
302.4500 0.55 (0.18%)
NSE Sep 24, 2025 15:31 PM
Volume: 61,514
 

302.45
0.18%
Prabhudas Lilladhar
last eight quarters. INDR maintains robust guidance in US generics with growth of 67%/24% in FY22E/FY23E. Its business expansion will drive 25%+ growth in Europe. We note that India formulation sales growth of more than 17% with revenue contribution of 55-60% will have multiplier benefit on sales and headline margins going forward. This along with strong and sustainable growth in US will improve EBITDA margin from 15-16% to 18-20% in FY22E23E. We maintain our positive outlook on INDR as we believe that 1) MR productivity would improve to Rs3lakhs/month (from Rs2.5lakh/month) along with existing field force, 2) India formulations growth to return to more than...
Indoco Remedies Ltd. has gained 28.60% in the last 6 Months
More from Indoco Remedies L…
All earning calls
Investor presentations from Indoco Remedies L…
All investor presentations